The tiny editor has some big features.

THIS is the terrifying moment an airport roof rips wide open and water begins gushing into the terminal as passengers run for cover. Water surged from a huge gaping hole in the international airport ...

AI chatbots make it possible for people who can’t code to build apps, sites and tools. But it’s decidedly problematic.

"Brentwood Go" is a unique rideshare service that's coming to a stop on Monday. "We've been offering rides to people in the community just to get around," said Israel Toledo, a driver for Brentwood Go ...

PHILADELPHIA (WPVI) -- For the fifth year in a row, Reading Terminal Market is in the running for USA Today's "10 Best" title of "Best Public Market in America." It secured the top spot in 2021 and ...

Subscribe to Marlin magazine and get a year of highly collectible, keepsake editions – plus access to the digital edition and archives. Sign up for the free Marlin email newsletter. So, you want to ...

Florida's Python Elimination Program pays certified hunters to remove the invasive snakes from the Everglades. Burmese pythons have caused a severe decline in native small mammal populations in South ...

EDMONDS, Wash. — Syreh Sonko is studying nursing at Edmonds College through Washington state's Running Start, but the program that's saving her nearly $30,000 in college costs may soon look different.

State lawmakers might reduce funding for Running Start, a program that lets high school juniors and seniors take courses and earn credits at community and technical colleges. Running Start students ...

BP has suspended its share buyback program and increased its cost-cutting goal by $1.5 billion to bolster its balance sheet and increase investment in oil production. The company's current struggles ...

John Maynard Keynes once wrote, “The difficulty lies, not in the new ideas, but in escaping from the old ones”: an apt depiction of the current discourse and debate of what the world will look like ...

Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.